CD19 and acute lymphoblastic leukemia: Anti-CD19 CAR-T cells have achieved complete response (CR) rates ranging from approximately 50% to over 90% in patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphomas [2,3].